|
MX2015013845A
|
|
Tiotropium dry powders.
|
|
AU2012258353A1
|
|
Formulations for alteration of biophysical properties of mucosal lining
|
|
US2014336159A1
|
|
Methods for treating and diagnosing respiratory tract infections
|
|
AU2012202618A1
|
|
Formulations for decreasing infectivity of pulmonary disease
|
|
WO2012064601A1
|
|
Methods of treating and preventing rhinovirus infection
|
|
CN103228273A
|
|
Monovalent metal cation dry powders for inhalation
|
|
EP2464346A1
|
|
Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
|
|
WO2012012498A2
|
|
Use of trp channel agonists to treat infections
|
|
NZ621065A
|
|
Dry powder formulations and methods for treating pulmonary diseases
|
|
AU2010229724A1
|
|
Pharmaceutical formulations and methods for treating respiratory tract infections
|
|
CN102448439A
|
|
Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
|
|
AU2010229721A1
|
|
Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
|
|
CN102448438A
|
|
Anti-influenza formulations and methods
|
|
CA2649442A1
|
|
Diagnostic device for determining particle production
|
|
KR20080018872A
|
|
Formulations for alteration of biophysical properties of mucosal lining
|
|
AU2006244478A1
|
|
Ultrasonic aerosol generator
|
|
AU2006205108A1
|
|
Method and device for decreasing contamination
|
|
CN101137325A
|
|
Method and device for decreasing contamination
|
|
US2005207983A1
|
|
Formulations decreasing particle exhalation
|
